Clinical Trial

Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated January 13, 2025 (before its estimated October 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a prospective, single-arm Phase 2 study to evaluate the efficacy and safety of mitoxantrone hydrochloride liposome injection combined with PD-1 blockade in patients with recurrent (not unable to locally curative treatment) or metastatic NPC who failed at least first-line platinum-containing standard regimen and/or anti PD-1/L1.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-06-23.
Status change: Not Yet Recruiting → Recruiting 2025-01-09
Trial Details
NCT Number NCT06472713
Lead Sponsor Ming-Yuan Chen
Conditions Recurrent or Metastatic Nasopharyngeal Carcinoma
Enrollment 32 participants
Start Date 2024-07-20
Primary Completion 2025-10-31 (estimated)
Study Completion 2027-09-30 (estimated)
Updated on ClinicalTrials.gov 2025-01-13